Viridian Therapeutics
VRDN
5 hedge funds and large institutions have $626K invested in Viridian Therapeutics in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
10% more capital inflows, than outflows
Capital inflows: $47.5K | Capital outflows: $43.2K
0% more funds holding
Funds holding: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
3.28% less ownership
Funds ownership: 6.56% → 3.29% (-3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Heartland Advisors
Milwaukee,
Wisconsin
|
+$37.4K |
| 2 |
Citigroup
New York
|
+$1.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$43.2K |
VRDN Hedge Fund Activity: Q4 2014 in Review
5 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2014, worth a combined $626K — down 44% from $1.12M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VRDN positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Heartland Advisors, adding an estimated $37.4K. The largest seller was Perkins Capital Management, cutting an estimated $43.2K.
- 5 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $626K of Viridian Therapeutics stock for Q4 2014, down 44% quarter-over-quarter.
- 2 funds opened new Viridian Therapeutics positions in Q4 2014 and 0 closed out, a net change of +2 holders.
- The largest Viridian Therapeutics buyer in Q4 2014 was Heartland Advisors, an estimated $37.4K added.
- The largest Viridian Therapeutics seller in Q4 2014 was Perkins Capital Management, an estimated $43.2K sold.
Based on aggregated 13F filings for Q4 2014.